This trial is testing a new cancer treatment that involves delivering genetically-modified T cells into the brain. The goal is to find the best dose and to assess side effects.
2 Primary · 17 Secondary · Reporting Duration: Up to 15 years
Experimental Treatment
39 Total Participants · 1 Treatment Group
Primary Treatment: Chimeric Antigen Receptor T-Cell Therapy · No Placebo Group · Phase 1
Age 18 - 75 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: